TY - JOUR
T1 - Ethylphenidate formation in human subjects after the administration of a single dose of methylphenidate and ethanol
AU - Markowitz, John S.
AU - Devane, C. Lindsay
AU - Boulton, David W.
AU - Nahas, Ziad
AU - Risch, S. Craig
AU - Diamond, Fran
AU - Patrick, Kennerly S.
PY - 2000
Y1 - 2000
N2 - Ethylphenidate was recently reported as a novel drug metabolite in two overdose fatalities where there was evidence of methylphenidate and ethanol congestion. This study explores the pharmacokinetics of ethylphenidate relative to methylphenidate and the major metabolite ritalinic acid, in six healthy subjects who received methylphenidate and ethanol under controlled conditions. Subjects (three males, three females) received a single oral dose of methylphenidate (20 mg; two 10-mg tablets) followed by consumption of ethanol (0.6 g/kg) 30 min later. Methylphenidate, ritalinic acid, and ethylphenidate were quantified using liquid chromatography-tandem mass spectrometry. Ethylphenidate was detectable in the plasma and urine of all subjects after ethanol ingestion. The mean (±S.D.) area under the concentration versus time curve for ethylphenidate was 1.2 ± 0.7 ng/ml/h, representing 2.3 ± 1.3% that of methylphenidate (48 ± 12 ng/ml/h). A significant correlation was observed between the area under the concentration versus time curve of methylphenidate and that of ethylphenidate. In view of the known dopaminergic activity of racemic ethylphenidate, it remains possible that under certain circumstances of higher level dosing, e.g., in the abuse of methylphenidate and ethanol, the metabolite ethylphenidate may contribute to drug effects.
AB - Ethylphenidate was recently reported as a novel drug metabolite in two overdose fatalities where there was evidence of methylphenidate and ethanol congestion. This study explores the pharmacokinetics of ethylphenidate relative to methylphenidate and the major metabolite ritalinic acid, in six healthy subjects who received methylphenidate and ethanol under controlled conditions. Subjects (three males, three females) received a single oral dose of methylphenidate (20 mg; two 10-mg tablets) followed by consumption of ethanol (0.6 g/kg) 30 min later. Methylphenidate, ritalinic acid, and ethylphenidate were quantified using liquid chromatography-tandem mass spectrometry. Ethylphenidate was detectable in the plasma and urine of all subjects after ethanol ingestion. The mean (±S.D.) area under the concentration versus time curve for ethylphenidate was 1.2 ± 0.7 ng/ml/h, representing 2.3 ± 1.3% that of methylphenidate (48 ± 12 ng/ml/h). A significant correlation was observed between the area under the concentration versus time curve of methylphenidate and that of ethylphenidate. In view of the known dopaminergic activity of racemic ethylphenidate, it remains possible that under certain circumstances of higher level dosing, e.g., in the abuse of methylphenidate and ethanol, the metabolite ethylphenidate may contribute to drug effects.
UR - http://www.scopus.com/inward/record.url?scp=0034090152&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034090152&partnerID=8YFLogxK
M3 - Article
C2 - 10820132
AN - SCOPUS:0034090152
SN - 0090-9556
VL - 28
SP - 620
EP - 624
JO - Drug Metabolism and Disposition
JF - Drug Metabolism and Disposition
IS - 6
ER -